Personalis Inc (PSNL) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Personalis Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Personalis Inc's ROI in the second quarter of 2026?
Personalis Inc recorded a cumulative net loss of $-107 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -40.7%.
Within the Healthcare sector 426 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3289 to 3611.
Advancements in Cancer Monitoring: Evaluating Personalis Inc. Amid Financial ChallengesThe landscape of cancer diagnostics and monitoring continues to evolve, with innovative technologies playing a pivotal role in early detection and patient management. Recent developments from Personalis, Inc. (Nasdaq: PSNL) showcase both promising advancements in cancer care and the financial hurdles the company faces. At the recent European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, Personalis presented new data on its NeXT Personal minimal residual disease (MRD) test, a cutting-edge assay aimed at identifying and tracking recurrence in cancer patients through the detection of circulating tumor DNA (ctDNA) in blood samples. Breakthrough in MRD TestingLaunched in late 2023, the NeXT Personal assay has garnered attention for its potential to revolutionize the monitoring of cancer patients. MRD testing is crucial as it provides insights into the effectiveness of treatment and the likelihood of cancer recurrence. By identifying even the smallest traces of ctDNA, the NeXT Personal test promises to enhance the personalization of care, leading to better patient outcomes. Given the increasing importance of targeted therapies and personalized medicine, the role of assays that accurately measure MRD cannot be overstated.
In a significant development for cancer diagnostics, biotech companies Personalis, Inc. and Tempus AI, Inc. have expanded their collaboration to bring ultra-sensitive minimal residual disease (MRD) testing to market. This announcement, made in November 2023, was officially marked by a launch at the American Society of Clinical Oncology (ASCO) meeting earlier this month, highlighting a promising step forward in the quest for more precise cancer treatment options. A Strategic Alliance for Better Cancer OutcomesPersonalis, based in Fremont, California, is renowned for its sophisticated genomic sequencing and analytics technologies aimed at tailoring immuno-oncology therapies. Tempus, famously recognized for its data-driven precision medicine approach, is leveraging its capabilities to act as the exclusive commercial partner for Personalis’ ultra-sensitive tumor-informed MRD testing product. This partnership is poised to make significant waves in oncology, particularly for breast and lung cancer patients.
In a significant advancement within the oncology landscape, Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) have announced an expanded collaboration aimed at commercializing ultra-sensitive minimal residual disease (MRD) testing. This partnership, officially disclosed in November 2023, aims to bring enhanced diagnostic capabilities to the medical community, specifically targeting breast and lung cancers.The collaboration emerged in the wake of increased demand for precise and reliable cancer monitoring solutions. Personalis, a leader in genomics and personalized medicine, has developed an ultra-sensitive tumor-informed MRD testing product designed to detect residual cancer cells following treatment. This testing methodology is pivotal, as its high sensitivity can significantly improve patient outcomes by enabling clinicians to make informed decisions regarding ongoing treatment strategies.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
